Fellow Eye Anti-VEGF 'Crunch' Effect in Retinopathy of Prematurity

Ophthalmic Surg Lasers Imaging Retina. 2018 Sep 1;49(9):e102-e104. doi: 10.3928/23258160-20180907-16.

Abstract

Background and objective: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation.

Patients and methods: Retrospective case report and literature review.

Results: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only.

Conclusion: The authors present the first reported case, to their knowledge, of a "crunch" phenomenon tractional retinal detachment from fellow eye administration of bevacizumab. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:e102-e104.].

Publication types

  • Case Reports
  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Bevacizumab / adverse effects*
  • Female
  • Gestational Age
  • Humans
  • Infant
  • Infant, Extremely Low Birth Weight
  • Intravitreal Injections
  • Retinal Detachment / etiology*
  • Retinal Detachment / surgery
  • Retinopathy of Prematurity / drug therapy*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitrectomy

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab